0001209191-22-059938.txt : 20221206 0001209191-22-059938.hdr.sgml : 20221206 20221206085050 ACCESSION NUMBER: 0001209191-22-059938 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221206 DATE AS OF CHANGE: 20221206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lochner Daniel CENTRAL INDEX KEY: 0001791187 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 221446767 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE109 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-01 0 0001720725 Oyster Point Pharma, Inc. OYST 0001791187 Lochner Daniel C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 106 PRINCETON NJ 08540 0 1 0 0 Chief Financial Officer Common Stock 2022-12-01 4 F 0 3258 11.20 D 74463 D The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units (the "RSUs"). Such RSUs were previously reported on the Reporting Person's Form 4 as to (i) 11,222 filed with the Securities and Exchange Commission on February 2, 2021 (the "2021 Award"); and (ii) 19,500 filed with the Securities and Exchange Commission on January 11, 2022 (the "2022 Award"). 2,805 RSUs of the 2021 Award and 4,875 RSUs of the 2022 Award were subsequently accelerated, effective December 1, 2022, resulting in the withholding being reported herein. /s/ Brandon Fenn, Attorney-in-Fact 2022-12-06